Academic Journal
CARDIAC PROTECTIVE INOTROPIC THERAPY – OPPORTUNITIES AND PROSPECTIVE OF USING LEVOSIMENDAN IN CARDIAC SURGERY ; КАРДИОПРОТЕКТИВНАЯ ИНОТРОПНАЯ ТЕРАПИЯ – ВОЗМОЖНОСТИ И ПЕРСПЕКТИВЫ ПРИМЕНЕНИЯ ЛЕВОСИМЕНДАНА В КАРДИОХИРУРГИИ
| العنوان: | CARDIAC PROTECTIVE INOTROPIC THERAPY – OPPORTUNITIES AND PROSPECTIVE OF USING LEVOSIMENDAN IN CARDIAC SURGERY ; КАРДИОПРОТЕКТИВНАЯ ИНОТРОПНАЯ ТЕРАПИЯ – ВОЗМОЖНОСТИ И ПЕРСПЕКТИВЫ ПРИМЕНЕНИЯ ЛЕВОСИМЕНДАНА В КАРДИОХИРУРГИИ |
|---|---|
| المؤلفون: | V. V. Pasyuga, V. V. Lomivorotov, A. A. Eremenko, В. В. Пасюга, В. В. Ломиворотов, А. А. Еременко |
| المصدر: | Messenger of ANESTHESIOLOGY AND RESUSCITATION; Том 13, № 2 (2016); 70-77 ; Вестник анестезиологии и реаниматологии; Том 13, № 2 (2016); 70-77 ; 2541-8653 ; 2078-5658 |
| بيانات النشر: | NEW TERRA Publishing House |
| سنة النشر: | 2018 |
| المجموعة: | Messenger of ANESTHESIOLOGY AND RESUSCITATION / Вестник анестезиологии и реаниматологии |
| مصطلحات موضوعية: | сердечная недостаточность, levosimendan, cardiac surgery, heart failure, левосимендан, кардиохирургия |
| الوصف: | Pharmacological support of the circulation remains to be a corner stone when managing patients with myocardial dysfunction. The article reviews the current theoretical and practical aspects of using levosimendan in cardiac surgery as an inotropic medication with the unique action mechanism and cardio-protective properties. ; Фармакологическая поддержка циркуляции до сих пор является краеугольным камнем при ведении пациентов с миокардиальной дисфункцией. В статье рассмотрены современные теоретические и практические аспекты использования левосимендана в кардиохирургии как инотропного препарата с уникальным механизмом действия и кардиопротективными свойствами. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | Russian |
| Relation: | https://www.vair-journal.com/jour/article/view/90/128; Григорьев E. В., Торопова Я. Г., Плотников Г. П. и др. Фармакологическая кардиопротекция при реперфузии изолированного сердца // Анестезиол. и реаниматол. – 2015. – № 2. – C. 12–16.; Еременко А. А., Колпаков П. Е., Бабаев М. А. и др. Применение левосимендана у кардиохирургических больных с хронической сердечной недостаточностью // Анестезиол. и реаниматол. – 2010. – № 2. – C. 24–27.; Ломиворотов В. В., Еременко А. А., Бобошко В. А. и др. Периоперационное использование левосимендана в кардиохирургии // Патология кровообращения и кардиохирургия. – 2015. – Т. 19, № 2. – С. 113–123.; Abraham W., Adams K., Fonarow G. et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medication: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE) // J. Am. Coll. Cardiol. – 2005. – Vol. 46. – P. 57–64.; Adamopoulos S., Parissis J., Iliodromitis E. et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure // Am. J. Cardiol. – 2006. – Vol. 98. – P. 102–106.; Alvarez J., Baluja A., Selas S. et al. A comparison of dobutamine and levosimendan on hepatic blood flow in patients with a low cardiac output state after cardiac surgery: a randomised controlled study // Anaesth. Int. Care. – 2013. – Vol. 41. – P. 719–727.; Bassani R. A., Bassani J. W., Bers D. M. et al. Relaxation in ferret ventricular myocytes: role of the sarcolemmal Ca++ATPase // Pflugers Atchiv. – 1995. – Vol. 430. – P. 573–578.; Baysal A., Yanartas M., Dogukan M. et al. N. Levosimendan improves renal outcome in cardiac surgery: a randomised trial // J. Cardiothorac. Vasc. Anesth. – 2014. – Vol. 28. – P. 586–594.; Bers D. M., Measurment of Calcium transport in heart using modern approaches // New Horizons. – 1996. – Vol. 4. – P. 36–44.; Bers D. M. Calcium fluxes involved in control of cardiac myocyte contraction // Circ. Res. – 2000. – Vol. 87. – P. 275–281.; Bers D. M. Cardiac excitation-contraction coupling // Nature. – 2001. – Vol. 415. – P. 198–205.; Blinks J. R., Endoh M. Modification of myofibrillar responsiveness to Ca2+ as an inotropic mechanism // Circulation. – 1986. – Vol. 73. – Р. III85–III98.; Caimmi P. P., Kapetanakis E. I., Beggino C. et al. Management of acute cardiac failure by intracoronary administration of levosimendan // J. Cardiovasc. Pharmacol. TM. – 2011. – Vol. 58. – P. 246–253.; Cammarata G. A., Weil M. H., Sun S. et al. Levosimendan improves cardiopulmonary resuscitation and survival by K(ATP) channel activation // J. Am. Coll. Cardiol. – 2006. – Vol. 47. – P. 1083–1085.; Chen Q., Camara A. K., Rhodes S. S. et al. Cardiotonic drugs differentially alter cytosolic [Ca2+] to left ventricular relationships before and after ischemia in isolated guinea pig hearts // Cardiovasc. Res. – 2003. – Vol. 59. – P. 912–925.; de Hert S. G., Lorsomradee S., vanden Eede H. et al. A randomized trial evaluating different modalities of levosimendan administration in cardiac surgery patients with myocardial dysfunction // J. Cardiothor. Vasc. Anesthesia. – 2008. – Vol 22, № 5. – P. 699–705.; Diaz M. E., Graham H. K., O’Neill S. C. et al. The control of carcoplasmic reticulum Ca2+content in cardiac muscle // Cell. Calcium. – 2005. – Vol. 38. – P. 391–396.; Dickstein K., Cohen-Solal A., Filippatos G. et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the heart failure association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) // Eur. Heart J. – 2008. – Vol. 29. – P. 2388–2442.; du Toit E. F., Genis A., Opie L. H. et al. A role for the RISK pathway and K(ATP) channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart // Br. J. Pharmacol. – 2008. – Vol. 154. – P. 41–50.; Edes I., Kiss E., Kitada Y. et al. Effects of levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart // Circ Res. – 1995. – Vol. 77. – P. 107–113.; Endoh M., Hori M. Acute heart failure: inotropic agents and their clinical uses // Expert. Opin Pharmacother. – 2006. – Vol. 7. – P. 2179–2202.; Erdei N., Papp Z., Pollesello P. et al. The levosimendan metabolite OR–1896 elicits vasodilation by activating the K (ATP) and BK(Ca) channels in rat isolated arterioles // Br. J. Pharmacol. – 2006. – Vol. 148. – P. 696–702.; Fonarow G. C., Heywood J. T., Heidenreich P. A. et al. Temporal trends in clinical characteristics, treatments and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE) // Am. Heart J. – 2007. – Vol. 153. – P. 1021–1028.; Giannakoulas G., Giannoglou G., Vassilikos V. et al. Clinical significance of acute neurohormonal response after levosimendan treatment // Am. J. Cardiol. – 2006. – Vol. 98. – P. 1123–1124.; Goetzenich A., Hatam N., Preuss S. et al. The role of hypoxia-inducible factor-1α and vascular endothelial growth factor in late-phase preconditioning with xenon, isoflurane and levosimendan in rat cardiomyocytes // Interact. Cardiovasc. Thorac. Surg. – 2014. – Vol. 18, № 3. – P. 321–328.; Greco T., Calabrò M. G., Covello R. D. et al. Bayesian network meta-analysis on the effect of inodilatory agents on mortality // Br. J. Anaesth. – 2015. – Vol. 114, № 5. – P. 746–756.; Grossini E., Caimmi P. P., Molinary C. et al. Hemodynamic effect of intracoronary administration of levosimendan in the anesthetized pig // J. Cardiovasc. Pharmacol. – 2006. – Vol. 46. – P. 333–342.; Haikala H., Nissinen E., Etemzadeh E. et al. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation // J. Cardiovasc. Pharmacol. – 1995. – Vol. 25. – P. 794–801.; Harrison R. W., Hasselblad V., Mehta R. H. et al. Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis // J. Cardiothor. Vascular Anesthesia. – 2013. – Vol. 27, № 6. – P. 1224–1232.; Honisch A., Theuring N., Ebner B. et al. Postconditioning with levosimendan reduces the infarct size involving the PI3K pathway and KATP-channel activation but is independent of PDE-III inhibition // Basic. Res. Cardiol. – 2009. – Vol. 105. – P. 155–167.; Jamali I. N., Kersten J. R., Pagel P. S. et al. Intracoronary levosimendan enhances contractile function of stunned myocardium // Anesth. Analg. – 1997. – Vol. 85. – P. 23–29.; Landoni G., Augoustides J. G., Guarracino F. et al. Mortality reduction in cardiac anesthesia and intensive care: Results of the Firs International Consensus Conference // Acta Anaesthesiol. Scand. – 2011. – Vol. 55. – P. 259–266.; Landoni G., Biondi-Zoccai G., Greco M., et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies // Crit. Care Med. – 2012. – Vol. 40. – P. 634–646.; Landoni G., Mizzi A., Biondi-Zoccai G. et al. Reducing mortality in cardiac surgery with levosimendan: a meta-analysis of randomized controlled trials // J. Cardiothorac. Vascular Anesthesia. – 2010. – Vol 24, № 1. – P. 51–57.; Levin R., Degrange M., Del Mazo C. et al. Preoperative levosimendan decreases mortality and the development of low cardiac output in high–risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass // Exp. Clin. Cardiol. – 2012. – Vol. 17. – P. 125–130.; Lochner A., Colesky F., Genade S. Effect of a calcium-sensitizing agent, levosimendan, on the postcardioplegic inotropic response of the myocardium // Cardiovasc. Drugs Ther. – 2000. – Vol. 14. – P. 271–281.; Maharaj R., Metaxa V., Levosimendan and mortality after coronary revascularisation: a meta-analysis of randomised controlled trials // Crit. Care. – 2011. – Vol. 15. – Р. R140.; Mebazaa A., Nieminen M. S., Packer M. et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVED Randomized Trial // JAMA. – 2007. – Vol. 297. – P. 1883–1891.; Niu Z. Z., Wu S. M., Sun W. Y. et al. Perioperative levosimendan therapy is associated with a lower incidence of acute kidney injury after cardiac surgery: a meta-analysis // J. Cardiovasc. Pharmacol. – 2014. – Vol. 63. – P. 107–112.; Packer M., Carver J. R., Rodeheffer R. J. at al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group // N. Engl. J. Med. – 1991. – Vol. 325. – P. 1468–1475.; Papp J. G., Pollesello P., Varro A. F. et al. Effect of levosimendan and milrinone on regional myocardial ischemia/reperfusion-induced arrhythmias in dogs // J. Cardiovasc. Pharmacol. Ther. – 2006. – Vol. 11. – P. 129–135.; Papp Z., Edes I., Fruhwald S. et al. Levosimendan: Molecular mechanisms and clinical implications consensus of experts on the mechanisms of action of levosimendan // Int. J. Cardiol. – 2012. – Vol. 159, № 2. – P. 82–87.; Parissis J. T., Adamopoulos S., Antoniades C. et al. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure // Am. J. Cardiol. – 2004. – Vol. 93. – P. 1309–1312.; Parissis J. T., Andreadou I., Markantonis S. L. et al. Effects of levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure // Atherosclerosis. – 2007. – Vol. 195. – Р. e210–е215.; Parissis J. T., Karavidas A., Bistola V. et al. Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure // Atherosclerosis. – 2008. – Vol. 197. – P. 278–282.; Robertson I. M., Sun Y. B., Li M. X. et al. A structural and functional perspective into the mechanism of Ca++-sensitizers that target the cardiac troponin complex // J. Mol. Cell. Cardiol. – 2010. – Vol. 49, № 6. – P. 1031–1041.; Sorsa T., Heikkinen S., Abbott M. B. et al. Binding of levosimendan, a calcium sensitizer, to cardiac troponin C // J. Biol. Chem. – 2001. – Vol. 276. – P. 9337–9343.; Sorsa T., Pollesello P., Rosevear P. R. et al., Stereoselective binding of levosimendan to cardiac troponin C causes Ca2+-sensitization // Eur. J. Pharmacol. – 2004. – Vol. 486. – P. 1–8.; Sponga S., Ivanitskaia E., Potapov E. et al. Preoperative treatment with levosimendan in candidates for mechanical circulatory support // ASAIO J. – 2012. – Vol. 58. – P. 6–11.; Szilágyi S., Pollesello P., Levijoki J. et al. The effects of levosimendan and OR– 1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig // Eur. J. Pharmacol. – 2004. – Vol. 486. – P. 67–74.; Theiss H. D., Grabmaier U., Kreissl N. et al. Preconditioning with levosimendan before implantation of left ventricular assist devices // Artif. Organs. – 2014. – Vol. 38. – P. 231–234.; Toller W., Algotsson L., Guarracino F. et al. Perioperative use of levosimendan: best practice in operative settings // J. Cardiothor. Vascular Anesthesia. – 2013. – Vol. 27, № 2. – P. 361–366.; Toller W., Heringlake M., Guarracino F. et al. Preoperative and perioperative use of levosimendan in cardiac surgery European expert opinion // Int. J. Cardiology. – 2015. – Vol. 184. – P. 323–336.; Tritapepe L., de Santis V., Vitale D. et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery // Brit. J. Anaesthesia. – 2009. – Vol. 102, № 2. – P. 198–204.; https://www.vair-journal.com/jour/article/view/90 |
| DOI: | 10.21292/2078-5658-2016-13-2-70-77 |
| الاتاحة: | https://www.vair-journal.com/jour/article/view/90 https://doi.org/10.21292/2078-5658-2016-13-2-70-77 |
| Rights: | Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). ; Авторы, публикующие в данном журнале, соглашаются со следующим:Авторы сохраняют за собой авторские права на работу и предоставляют журналу право первой публикации работы на условиях лицензии Creative Commons Attribution License, которая позволяет другим распространять данную работу с обязательным сохранением ссылок на авторов оригинальной работы и оригинальную публикацию в этом журнале.Авторы сохраняют право заключать отдельные контрактные договорённости, касающиеся не-эксклюзивного распространения версии работы в опубликованном здесь виде (например, размещение ее в институтском хранилище, публикацию в книге), со ссылкой на ее оригинальную публикацию в этом журнале.Авторы имеют право размещать их работу в сети Интернет (например в институтском хранилище или персональном сайте) до и во время процесса рассмотрения ее данным журналом, так как это может привести к продуктивному обсуждению и большему количеству ссылок на данную работу (См. The Effect of Open Access). |
| رقم الانضمام: | edsbas.29F17A9 |
| قاعدة البيانات: | BASE |
| DOI: | 10.21292/2078-5658-2016-13-2-70-77 |
|---|